Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DimerixASX:DXB -5.17%30 Days Sales Outstanding is 142.33 as of Dec. 2025, which is 44% below its 10-year median of 252.56. GuruFocus rates ASX:DXB with a GF Score™ of 30/100. The stock has 3 warning signs investors should review. Among 836 Biotechnology companies, Dimerix ranks better than 61.12% on this metric.
Dimerix's average Accounts Receivable for the
six
months ended in Dec. 2025 was A$1.65 Mil. Dimerix's Revenue for the
six
months ended in Dec. 2025 was A$2.12 Mil.
Hence, Dimerix's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 142.33.
The historical rank and industry rank for Dimerix's Days Sales Outstanding or its related term are showing as below:
ASX:DXB'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 34.3 Med: 252.56 Max: 470.82
Current: 56.01
During the past 13 years, Dimerix's highest Days Sales Outstanding was 470.82. The lowest was 34.30. And the median was 252.56.
ASX:DXB's Days Sales Outstanding is ranked better than 61.12% of 836
companies
in the Biotechnology industry
Industry Median: 68.96
vs ASX:DXB: 56.01
Dimerix's Days Sales Outstanding
declined
from Dec. 2024 (365.64) to Dec. 2025 (142.33).
Dimerix (ASX:DXB) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Dimerix Days Sales Outstanding Related Terms
Dimerix Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Dimerix's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:DXB vs VRTX, REGN, RVMD: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Dimerix's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dimerix Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dimerix's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Dimerix's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 142.33 mean?
Dimerix (ASX:DXB) has a Days Sales Outstanding of 142.33 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Dimerix and its competitors. This is 44% below median its historical median of 252.56. Over the past decade, Dimerix's Days Sales Outstanding has ranged from 34.30 to 470.82. According to the industry distribution chart, Dimerix ranks #325 out of 836 companies in the Biotechnology industry, placing it in the top 38.9%.
Is Dimerix's Days Sales Outstanding too high?
Dimerix's current Days Sales Outstanding of 142.33 is 44% below median its 10-year median of 252.56. Over the past 10 years, this metric has ranged from a low of 34.30 to a high of 470.82. The Biotechnology industry median Days Sales Outstanding is 68.96. Dimerix's value of 142.33 is 106.4% above this industry median. Based on the distribution chart, Dimerix ranks #325 out of 836 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Dimerix has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Dimerix's Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Dimerix ranks #325 out of 836 companies for Days Sales Outstanding. This puts Dimerix in the upper half of its industry. The industry median Days Sales Outstanding is 68.96. Dimerix's value of 142.33 is 106.4% above this benchmark. Historically, Dimerix's own Days Sales Outstanding has ranged from 34.30 to 470.82 over the past decade. While the company's 10-year median is 252.56 vs. the industry median of 68.96, Dimerix has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.96, based on 836 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dimerix's current Days Sales Outstanding of 142.33 is 106.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Dimerix and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dimerix's current Days Sales Outstanding is 142.33, which is 44% below median its own 10-year median of 252.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dimerix stock overvalued right now?
Dimerix (ASX:DXB) has a current Days Sales Outstanding of 142.33. The current Days Sales Outstanding is 142.33, which is 44% below median its 10-year median of 252.56 and 106.4% above the Biotechnology industry median of 68.96. Dimerix's overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Dimerix (ASX:DXB), the current Days Sales Outstanding is 142.33 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Dimerix Ltd is a biopharmaceutical company developing new therapies in areas with unmet medical needs. The company is developing four product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for COPD, as well as the proprietary ReceptorHIT assay technology. It pursues new product concepts and applies deep scientific knowledge to the discovery of products from early-stage development through to commercialisation. Dimerix products will target multiple territories. The Group has only operated in one Segment, being investment in research and development of biopharmaceutical drugs.
30GF Score
Get the complete analysis for ASX:DXB
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:DXB has been successfully added to your 
